The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.10 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.55
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Wressle boosts Europa Oil, Egdon and Union Jack

Thu, 16th Dec 2021 10:56

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Shield Therapeutics PLC, up 27% at 37.00 pence, 12-month range 27.01p-66.00p. The Newcastle, England-based pharmaceutical company says patient access for its Accrufer iron deficiency product rises. Shield secures payer coverage with "several large pharmacy benefit managers" in US. This boosts Accrufer access to roughly 40 million patients.

----------

Europa Oil & Gas Holdings PLC, up 15% at 1.24 pence, 12-month range 1.00p-2.20p. Rises on production update from Wressle hydrocarbon development in North Lincolnshire. Wressle has produced at an average of 666 barrels of oil per day over last seven day period. In early 2022, testing will be completed to see "full potential of the well". Europa holds a 30% stake in Wressle. Egdon Resources PLC also owns 30% and Union Jack Oil PLC 40%. Egdon shares are up 11% and Union Jack up 8.4%.

----------

Ceres Power, up 8.1% at 1,005.00 pence, 12-month range 820.50p-1,626.00p. Credit Suisse starts coverage of the stock with an Outperform rating and 1,450p price target.

----------

AIM - LOSERS

----------

boohoo Group PLC, down 16% at 115.56 p, 12-month range 110.00p-378.90p. Retailer lowers sales and margins guidance due to Omicron uncertainty and as product return rates hit net sales. For the financial year ending February 28, boohoo now expects net sales growth in the 12% to 14% range, cut from previous guidance of a rise of 20% to 25%. In three months to November 30, net sale rise 10% annually to GBP506.2 million from GBP460.7 million. On a two-year basis, net sales are 53% higher. Shares fall to a roughly five-year low.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
26 May 2020 08:58

Shield Therapeutics names Hans Peter Hasler as next chairman

(Sharecast News) - Pharmaceutical group Shield Therapeutics named Hans Peter Hasler as non-executive chairman of the company on Tuesday.

Read more
1 May 2020 13:28

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

Read more
1 May 2020 09:55

Shield Therapeutics FY revenues impacted by milestone repayment

(Sharecast News) - Pharmaceuticals outfit Shield Therapeutics warned on Friday that full-year revenues would be lower than originally anticipated after it had to repay a sizeable milestone payment.

Read more
22 Apr 2020 15:13

UK EXECUTIVE CHANGE SUMMARY: Shield Therapeutics Replaces Founder

UK EXECUTIVE CHANGE SUMMARY: Shield Therapeutics Replaces Founder

Read more
18 Mar 2020 07:33

Shield Therapeutics Starts Independent Review Into Feraccru Study

Shield Therapeutics Starts Independent Review Into Feraccru Study

Read more
17 Mar 2020 15:17

Shield launches review after spotting flaw in 'Feraccru' study

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on the 'AEGIS-H2H' clinical trial on Tuesday, the data of which was primarily designed to be used in health economic analyses, pricing and reimbursement applications, as well as marketing purposes.

Read more
27 Jan 2020 15:07

Shield Therapeutics 2019 Revenue To Drop But Will Meet Expectations

Shield Therapeutics 2019 Revenue To Drop But Will Meet Expectations

Read more
27 Jan 2020 08:09

Shield Therapeutics details year of 'material progress'

(Sharecast News) - Drugs developer Shield Therapeutics told investors on Monday that 2019 had been a year of "material progress", with a key success being the recent Federal Drug Administration approval of its iron deficiency treatment, Feraccru/Accrufer.

Read more
8 Jan 2020 09:45

Shield Therapeutics Gets China Licence Agreement For Feraccru/Accrufer

Shield Therapeutics Gets China Licence Agreement For Feraccru/Accrufer

Read more
15 Aug 2019 14:28

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP134,000 In Shares

(Alliance News) - Shield Therapeutics PLC on Thursday said Chair James Karis acquired shares in the pharmaceutical company following a transaction on Tuesday.Karis purchased 75,000 shares a

Read more
7 Aug 2019 12:02

Shield Therapeutics Narrows Interim Losses Amid Expenses Fall

(Alliance News) - Drugmaker Shield Therapeutics said on Wednesday a payment from a commercial partner contributed to a sharp revenue rise in the first half of the year.In the six months to

Read more
3 Jun 2019 10:27

Teva Appeals Shield Therapeutics European Drug Patent Win

LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd has filed a notice of appeal on a decision regarding a Shield in a

Read more
26 Apr 2019 18:19

DIRECTOR DEALINGS: Shield Therapeutics Medical Chief Buys Shares

LONDON (Alliance News) - Shield Therapeutics PLC said on Friday that Chief Medical Officer Mark Sampson and his wife Julia have purchased shares in the company on Thursday.Mark bought at a

Read more
24 Apr 2019 12:22

Shield Therapeutics' Feraccru Granted Use Extension In Switzerland

LONDON (Alliance News) - Shield Therapeutics PLC said on Wednesday said the Swiss Agency for Therapeutic Products has approved the Feraccru product to treat iron deficiency in adults with or is to

Read more
17 Apr 2019 18:11

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP40,000 In Shares

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.